Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 52,521,912
  • Shares Outstanding, K 132,114
  • Annual Sales, $ 2,248 M
  • Annual Income, $ -278,160 K
  • EBIT $ 265 M
  • EBITDA $ 321 M
  • 60-Month Beta 0.30
  • Price/Sales 24.25
  • Price/Cash Flow N/A
  • Price/Book 233.07

Options Overview Details

View History
  • Implied Volatility 49.78% (+1.01%)
  • Historical Volatility 37.91%
  • IV Percentile 85%
  • IV Rank 52.59%
  • IV High 68.01% on 04/08/25
  • IV Low 29.56% on 08/13/25
  • Expected Move (DTE 5) 19.75 (4.97%)
  • Put/Call Vol Ratio 0.85
  • Today's Volume 1,928
  • Volume Avg (30-Day) 829
  • Put/Call OI Ratio 0.60
  • Today's Open Interest 33,277
  • Open Int (30-Day) 32,717
  • Expected Range 377.80 to 417.30

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 1.05
  • Number of Estimates 12
  • High Estimate 2.53
  • Low Estimate -0.02
  • Prior Year -0.65
  • Growth Rate Est. (year over year) +261.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
387.03 +2.72%
on 12/12/25
479.79 -17.14%
on 12/03/25
-55.19 (-12.19%)
since 11/12/25
3-Month
387.03 +2.72%
on 12/12/25
495.55 -19.78%
on 10/20/25
-68.34 (-14.67%)
since 09/12/25
52-Week
205.87 +93.11%
on 04/09/25
495.55 -19.78%
on 10/20/25
+152.29 (+62.09%)
since 12/12/24

Most Recent Stories

More News
Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027

Alnylam Pharmaceuticals, Inc. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has entered into separate, privately negotiated repurchase agreements with certain...

ALNY : 397.55 (-3.65%)
Alnylam Pharmaceuticals Announces Changes to Board of Directors

– Mike Bonney and Carolyn Bertozzi to Depart; Company Appoints Stuart Arbuckle as New Independent Director –

ALNY : 397.55 (-3.65%)
Is Vertex Pharmaceuticals Stock Underperforming the Nasdaq?

Vertex Pharmaceuticals has underperformed the broader Nasdaq index over the past year. However, Wall Street analysts remain moderately optimistic about its prospects.

$NASX : 23,195.17 (-1.69%)
VRTX : 452.04 (+1.37%)
ALNY : 397.55 (-3.65%)
The Biotech Boom Gets a Trading Tool: How Direxion's Titans ETF Gives Access to the Sector's Top Performers

Amid the biotechnology sector's transformative era the Direxion Daily Biotech Top 5 Bull 2X ETF ($TBXU) offers traders a new, single-trade solution to gain 2X daily leveraged exposure to an e

ALNY : 397.55 (-3.65%)
EXEL : 40.88 (-1.23%)
GILD : 120.40 (-2.28%)
INSM : 197.01 (+0.91%)
UTHR : 493.99 (+1.12%)
New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM

− Analyses Presented at the American Heart Association Scientific Sessions 2025 Underscore Vutrisiran’s Differentiated Profile – − Cardiovascular Magnetic Resonance...

ALNY : 397.55 (-3.65%)
Alnylam to Webcast Presentations at Upcoming November Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences: ...

ALNY : 397.55 (-3.65%)
Alnylam: Q3 Earnings Snapshot

Alnylam: Q3 Earnings Snapshot

ALNY : 397.55 (-3.65%)
Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress

− Generated Q3 2025 Total Net Product Revenues of $851 Million (103% Growth Compared with Q3 2024), Driven Primarily by Total TTR Revenues of $724 Million (135% Growth Compared with Q3 2024) – ...

ALNY : 397.55 (-3.65%)
Alnylam Pharma (ALNY) Gets a Hold from Leerink Partners

Leerink Partners analyst Mani Foroohar maintained a Hold rating on Alnylam Pharma yesterday and set a price target of $370.00. The company’s shares closed yesterday at $470.27.Elevate Your Investing...

ALNY : 397.55 (-3.65%)
Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2025 on Thursday,...

ALNY : 397.55 (-3.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference. The company's pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas - genetic medicines, cardio-metabolic...

See More

Key Turning Points

3rd Resistance Point 432.39
2nd Resistance Point 421.22
1st Resistance Point 409.38
Last Price 397.55
1st Support Level 386.37
2nd Support Level 375.20
3rd Support Level 363.36

See More

52-Week High 495.55
Last Price 397.55
Fibonacci 61.8% 384.89
Fibonacci 50% 350.71
Fibonacci 38.2% 316.53
52-Week Low 205.87

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar